Core Insights - IMUNON, Inc. is advancing its investigational DNA plasmid vaccine, IMNN-101, based on its proprietary PlaCCine technology platform, with upcoming presentations at major vaccine conferences [1][2][3] Group 1: Clinical Developments - IMUNON announced positive six-month data from the Phase 1 trial of IMNN-101, showing proof of concept for the PlaCCine technology, with better durability of protection compared to mRNA vaccines after a single dose targeting the SARS-CoV-2 Omicron XBB1.5 spike antigen variant [2] - IMNN-101 induced up to a 3-fold median increase in serum neutralizing antibody titers from baseline at six months, with stronger immune responses observed in higher dose cohorts [2] - The vaccine was reported to be safe and well tolerated, with no serious adverse effects noted [2] Group 2: Strategic Partnerships - To accelerate the development and commercialization of the PlaCCine platform, IMUNON is actively seeking strategic partnerships with leading pharmaceutical and biotechnology companies [3] - These collaborations aim to leverage PlaCCine's advantages, including enhanced durability, temperature stability, and scalable manufacturing, to address unmet needs in vaccines for infectious diseases and cancer [3] Group 3: Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body's natural mechanisms for safe and effective responses across various diseases [4] - The company is developing non-viral DNA technology, with its first modality, TheraPlas, aimed at gene-based delivery of cytokines for solid tumors, and the second modality, PlaCCine, for gene delivery of viral antigens [4] - IMUNON's lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, currently in Phase 3 clinical trials [5]